Navigation Links
EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer

HUNTSVILLE, Ala., June 3 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Khursheed Anwer, Ph.D., has been promoted to President and Chief Scientific Officer. He will succeed Danny H. Lewis, Ph.D., who has retired from the position of President and Chief Executive Officer. Dr. Lewis will continue to support the company on scientific and business affairs and retain his position on EGEN's Board of Directors.

"The Board would like to thank Dr. Lewis for his invaluable contributions over the past five years. Under Dr. Lewis' leadership EGEN has developed a proprietary technology platform, moved a novel cancer product through two human clinical trials, developed a family of RNAi delivery technologies and put the Company on solid financial footing. We are delighted that he will continue his contributions as a member of EGEN's Board of Directors," said Milton Harris, Ph.D., Chairman of EGEN. "At the same time, we are excited to have Dr. Anwer assume the role of President. He has demonstrated impressive strategic and leadership skills, advancing EGEN's science from the bench to the clinic. We are pleased to have him lead the continued development of EGEN's novel technology for RNAi delivery and clinical development of its oncology product."

"This is an excellent time to transition EGEN's leadership," said Dr. Lewis. "EGEN is in good shape on all fronts, but especially with the team of people EGEN has in all roles. It has been a pleasure to be part of this group. We are fortunate to have a scientific leader like Dr. Anwer available to take the helm."

Dr. Anwer possesses more than 15 years of management and scientific leadership experience in the biotechnology industry and has authored more than 40 publications during his active career in research and development. He has served EGEN in a variety of scientific leadership positions since 2002, most recently as Senior Vice-President and Chief Scientific Officer. In these positions he has led the execution of EGEN's proprietary discovery and development initiatives leading to EGEN's strong intellectual property position, was instrumental in building EGEN's research and development team and fostered important industry collaborations that are underway.

"I am pleased to have the opportunity to continue my personal contributions to EGEN's success," said Dr. Anwer. "I look forward to working with the Board of Directors and moving EGEN's technology forward to create additional value for our shareholders. We are poised to take the company's novel technology to the next level and make the promise of nucleic acid (DNA, RNAi) therapeutics become a reality."

About EGEN, Inc.

EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

For more information on EGEN, please visit .

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
2. Amylin Announces Preliminary Tabulation of Annual Meeting Results
3. Cynosure Announces Presentations at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
5. Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins
6. Valeritas Announces Appointment of New CEO
7. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
Post Your Comments:
(Date:10/13/2015)... , Oct. 13 2015 Research and ... "US & Europe Markets for Bone Morphogenetic Protein ... to their offering. --> ... that induce the formation of bone after a fracture. ... embryonic development in the formation of the skeleton. There ...
(Date:10/13/2015)... FLORHAM PARK, N.J. and SAN ... Corporation (BASF) and Mast Therapeutics, Inc. have agreed to ... 188.  Currently, excipient-grade poloxamer 188 NF, marketed by BASF ... polymer used in a variety of pharmaceutical and biological ... production. Poloxamer 188 is the starting material for Mast,s ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... distributor of automation systems, material handling solutions and components, is opening its latest ... near State Street, the facility is Exotic’s second major expansion in Metropolitan Detroit ...
(Date:10/13/2015)... the United States , ... represents about 14% of all new cases of kidney cancer.   ... Canada and Europe .  PRCC represents ... --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces ... AB (publ) ("AstraZeneca") have completed enrolment in a global Phase II ...
Breaking Biology Technology:
(Date:9/30/2015)... -- With nearly 300,000 Americans living with spinal cord injuries ... reach 12,500 annually, the role of Independent Living Centers ... Living (SCRS-IL) is increasingly important. SCRS-IL is one ... opening doors to independence for individuals with SCIs by ... technology services and education. "In serving people ...
(Date:9/30/2015)...  The global glucose monitoring device and diabetes management market ... new report on the industry from Kalorama Information. Sales in the ... followed by continuous glucose monitoring and sensor segment, according to ... these products in its latest report, The Global Glucose ... , ...
(Date:9/29/2015)...  iDAvatars is excited to be named one of the ... The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a demo ... "It is both an honor and a privilege ... to market the cognitive power of IBM Watson in our ...
Breaking Biology News(10 mins):